Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
Summary
Mineralys Therapeutics priced an upsized underwritten public offering of 9.8 million shares at $25.50 per share. The company expects to raise about $250 million in gross proceeds before fees and expenses. Mineralys plans to use the net proceeds to advance clinical development of lorundrostat, support research, manufacturing, and pre-commercialization work, and cover general corporate needs. The offering is expected to close around September 4, 2025, subject to customary conditions.
Funding
Amount
$250.0M
Total raised
Date
September 2, 2025
Announcement date
Investors
Wells Fargo Securities, Goldman Sachs
Lead investors
Company
mineralystx.com
Funded company
Classifications
industries
No industries detected
applications
Web and Content Management
AskAI Classifications
Labels
No AI classifications detected